AV Lopinavir

Version vom 11. April 2021, 08:19 Uhr

covers both lopinavir and ritonavir since the combination was in trials

32473994 2020. Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.
32271456 2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
32362644 2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use
32173576 2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
32331982 ä. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
32080993 2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32080992 2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32056407 2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32187464 ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19
32104907 ä. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus?A possible reference for coronavirus disease?19 treatment option
32369286 2020. A Trial of Lopinavir-Ritonavir in Covid-19 Reply
32273604 2020. Lopinavir-ritonavir in severe COVID-19
32114746 2020. Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer
32407513 2020. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
32473230 2020. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
32430428 2020. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
32474026 2020. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
32422065 2020. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
32385749 2020. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.
32492211 2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.
32495917 2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
32475183 2020. Does lopinavir measure up in the treatment of COVID-19?
32369285 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369284 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369283 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369282 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369281 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32443151 2020. Lopinavir pharmacokinetics in COVID-19 patients.

32578156 2020. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
32536150 2020. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
32556272 2020. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.
32569450 2020. Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective.
32598032 2020. Development and validation of a cost-effective and sensitive bioanalytical HPLC-UV method for determination of lopinavir in rat and human plasma.
32530369 2020. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.
32574332 2020. Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.
32438034 2020. Does lopinavir really inhibit SARS-CoV-2?
32539520 2020. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
32589165 2020. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
32611587 2020. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.
32616658 2020. BET 1: Lopinavir-ritonavir and COVID-19.
32621621 2020. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.
32629768 2020. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.
32641296 2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
32653015 2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
32678815 2020. Lopinavir-ritonavir para COVID-19: una revision sistematica viva.
32688374 2020. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.
32692462 2020. ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19.
32718719 2020. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.
32740371 2020. A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients.
32740371 2020. Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
32759053 2020. A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir.
32765274 2020. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
32767755 2020. Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.
32776298 2020. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
32776534 2020. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.
32786041 2020. Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir.
32790855 2020. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
32809882 2020. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
32838087 2020. Acute kidney injury associated with lopinavir/ritonavir combined therapy in patients with Covid-19.
32855060 2020. Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19 patient.
32856202 2020. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.
32858566 2020. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
32861965 2020. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
32869007 2020. Lopinavir-ritonavir associated acute kidney injury is not related to crystalluria in critically-ill COVID-19 patients.
32894567 2020. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
32918656 2020. Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.
32942923 2020. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
32953990 2020. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
33031764 2020. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.